Eurosurv. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

[tetano]

• Georgina Ireland[SUP]1,*[/SUP] , Heather Whitaker[SUP]2,*[/SUP] , Shamez N Ladhani[SUP]1,7[/SUP] , Frances Baawuah[SUP]1,3[/SUP] , Sathyvani Subbarao[SUP]1[/SUP] , Ezra Linley[SUP]4[/SUP] , Lenesha Warrener[SUP]5[/SUP] , Michelle O’Brien[SUP]3[/SUP] , Corinne Whillock[SUP]1[/SUP] , Oliver Martin[SUP]1[/SUP] , Paul Moss[SUP]6[/SUP] , Mary E Ramsay[SUP]1[/SUP] , Gayatri Amirthalingam[SUP]1,**[/SUP] , Kevin E Brown[SUP]1,**[/SUP]

Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.



[SUP]full article[/SUP]

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.1.2101114

 

[sharon sanders]

bump this